SEARCH

SEARCH BY CITATION

Keywords:

  • calcitriol;
  • keratinocyte;
  • skin;
  • UVB;
  • Vitamin D3

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Outlook
  5. Acknowledgements
  6. References

Abstract:  Irradiation of human keratinocytes with UVB (280–320 nm) in vitro and in vivo activates the metabolism of 7-dehydrocholesterol to hormonally active calcitriol. The production of calcitriol in the skin strongly depends on the photosynthesis of vitamin D3 which is biologically inactive in the first instance. Vitamin D3 serves as the starting substrate for two subsequent enzymatic hydroxylation steps in epidermal keratinocytes. Both the amount of vitamin D3 and the activity of anabolic and catabolic vitamin D hydroxylases determine the cutaneous level of calcitriol. The hormonally active metabolite of vitamin D3 regulates a huge number of genes in keratinocytes, and thus acts in an autocrine and/or paracrine manner. This local pathway of vitamin D3 is unique, but its relevance for healthy and diseased skin is widely unknown, yet. Experimental findings implicate several questions: (1) Is UVB-induced formation of calcitriol involved in regulation of growth and differentaition of epidermal cells as well as immunological and skin protective processes? (2) What endogenous and exogenous factors including drugs affect the cutaneous vitamin D3 pathway? From a therapeutical point of view, it has been known for a long time that topical application of calcitriol and its analogs can improve hyperproliferative skin diseases like psoriasis. In spite of many encouraging studies in recent years, the fields of the routinely therapeutical application of calcitriol or vitamin D analogs in dermatology (e.g. treatment of immunological, inflammatory, malignancies and infectious skin diseases) have not been intensified. Why is that?


Abbreviations:
UVB

ultraviolet B

7-DHC

7-dehydrocholesterol

DBP

vitamin D-binding protein

VDR

vitamin D receptor

VDRE

vitamin D response element

Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Outlook
  5. Acknowledgements
  6. References

Calcitriol (1α,25-dihydroxyvitamin D3, 1α,25(OH)2D3), the hormonally active vitamin D3 metabolite is mainly produced in the kidney after a cascade of reactions prefixed in liver and skin. It is well known for a long time that 1α,25(OH)2D3 maintains calcium homeostasis primarily by promoting the intestinal absorption of calcium and phosphorus, decreasing the clearance of these minerals from the kidney, and promoting bone mineralization (1). It is common knowledge today, that calcitriol exerts additional physiological functions including regulation of growth and differentiation in a broad variety of normal and malignant cells (2–5).

Human epidermal keratinocytes contain the complete machinery needed to produce the hormone 1α,25(OH)2D3 (calcitriol) from its initial precursor 7-dehydrocholesterol (7-DHC) (6–9). These cells also express the nuclear vitamin D receptor (VDR) that mediates the effects of this hormone on keratinocytes (10,11). Thus, it is reasonable to assume that calcitriol acts in an autocrine and paracrine manner in the epidermis. Recent evidence suggests that calcitriol produced in the skin may induce a number of biological actions which will be discussed in this review.

The vitamin D3 metabolism

Photochemical reactions in the skin

A photochemical reaction with maximum spectral effectiveness from 297 to 302 nm (UVB: 280–320 nm) results in the generation of previtamin D3 from 7-DHC (provitamin D3) in basal and suprabasal layers of the skin (Fig. 1) (1). By comparison, the shortest terrestrial solar wavelengths reaching the surface are ≈295 nm with the 295–320 nm range comprising ≈4% of the solar UV irradiance. UV radiation above 315 nm is unable to produce previtamin D3 in human skin. Photochemical conversion of 7-DHC to previtamin D3 in the skin proceeds rapidly. Previtamin D3 then undergoes thermal isomerization over a few hours and generates vitamin D3 (cholecalciferol). The vitamin D-binding protein (DBP) preferentially translocates vitamin D3 into the circulation, and the sequential activation of vitamin D3 happens in the liver and kidney. The serum level of 25OHD3 produced in the liver widely accounts for the ‘vitamin D status’ of the the body. In contrast, the serum level of 25OHD2 which derives from nutritional vitamin D2 is commonly very low in the majority of the European population (<3 ng/ml) (12).

image

Figure 1.  Vitamin D3 pathway in epidermal keratinocytes. (7-DHC, 7-dehydrocholesterol; CHOL, cholesterol; preD3, previtamin D3; 25OHD3, 25-hydroxyvitamin D3; 1α,25(OH)2D3, 1α,25-dihydroxyvitamin D3; 24R,25(OH)2D3, 24R,25-dihydroxyvitamin D3; 1α,24R,25(OH)3D3, 1α,24R,25-trihydroxyvitamin D3; 1α,25(OH)2-3-epi-D3, 1α,25-dihydroxy-3-epi-vitamin D3; CYP27A1, (27)25-hydroxylase; CYP27B1, 1α-hydroxylase; CYP24A1, 24-hydroxylase; Δ7-R, 7-DHC-Δ7-Reductase).

Download figure to PowerPoint

The minimal UVB radiation level that produces a significant increase of serum vitamin D3 was determined as being 18 mJ/cm2 for skin type II (13). Of relevance to public health is the finding that the threshold value of 18 mJ/cm2 is not generally reached during spring, fall and winter in North America and Europe (13). During prolonged exposure to the sun, both previtamin D3 and vitamin D3 undergo reversible photoisomerization to biologically inert sterols or previtamin D3 is subject to a back reaction leading to the regeneration of 7-DHC (Fig. 1) (14).

The 7-DHC level in normal human adult skin ranges between 1.9 and 75 μg/cm2 (15–19). An inverse relationship between the cutaneous 7-DHC concentration and age has been ascertained (20,21). Consistently, it was found by Holick et al. (21) that the amount of vitamin D3 in elderly subject’s circulation over the ensuing 72 h after exposure to simulated sunlight was about 30% of healthy young volunteers (skin type III, each). Other reports did not confirm such an inverse relationship, because responses in old and young volunteers (white-skinned) to artificial ultraviolet irradiation were quite similar (18). It should be noted, however, that spectral energy distribution of the UV lamps used in these studies was quite different, und may explain divergent findings. It seems, that only a small pool of 7-DHC in the upper layers of the epidermis is available for immediate conversion into previtamin D3 in response to ultraviolet irradiation, and this pool is only slowly replenished (18).

There is a biochemical equilibrium between 7-DHC and cholesterol which is adjusted by the activity of Δ7-reductase in epidermal keratinocytes. The conversion of 7-DHC into previtamin D3 in the skin depends on several individual and environmental factors including skin pigmentation (22), the solar zenith angle which depends on latitude, season and time of day (23–25) and usage of sunscreens (26–28). Some studies, however, have demonstrated that application of SPF 15 over a long time interval did not cause significant changes of the serum level of vitamin D3 (29–31).

The quantities of vitamin D3 synthesized by the skin are very small compared with the concentration of the precursor 7-DHC (assumed ≈2.000 ng/cm2). Human skin subjected to ultraviolet radiation in vivo produces up to 25 ng (1 IU) vitamin D3 per cm2 according to a conversion rate 1.3% (18,32). Other studies using foreskin exposed to summer sunlight have shown that formation of previtamin D3 may level off at approximately 7% of 7-DHC concentration (24). After whole-body UV irradiation of young adults with 1 MED the serum concentration of vitamin D3 reaches a maximum within 12–24 h and amounts to 20–30 ng/ml (800–1200 IU/l) (21,22,32,33).

Metabolism of vitamin D3

Vitamin D3 is stepwise hydroxylated in liver and kidney. The final product is hormonally active 1α,25(OH)2D3. This hormone acts locally in the kidney but is also transported by DBP to other target tissues that express VDR to operate in a genomic or nongenomic manner. However, the physiological serum concentration of calcitriol (10−11 to 10−11 m) is most likely too low to induce VDR-mediated hormonal effects in the skin (34,35). More than 99% of serum 1α,25(OH)2D3 is tightly bound to carriers such as DBP and albumin, and only 0.4% of the circulating 1α,25(OH)2D3 is free (35). Thus, the free plasma concentration of calcitriol approximates only around 6 × 10−13 m. Several studies have shown that inhibition of growth of human keratinocytes in vitro requires unbound calcitriol at concentrations higher than 10−8 m (equivalent to a highly unphysiological concentration of approximately 2.5 × 10−6 m total calcitriol in the circulating blood).

In vitro, many nonrenal cells, including keratinocytes, bone, placenta, prostate, macrophages, T-lymphocytes, dendritic cells and several cancer cells (e.g. from lung, prostate, and skin) can convert 25OHD3 to 1α,25(OH)2D3 (36–39). Several cell species including keratinocytes, macrophages, prostate epithelial cells and osteoblasts even express both 25-hydroxylase and 1α-hydroxylase activity which enables them to directly convert vitamin D3 to 1α,25(OH)2D3 (38,40–43). The efficient catalysis of substrate vitamin D3 to product 1α,25(OH)2D3 in these cells is dependent on several local factors in addition to the enzymes (CYP27A1 and CYP27B1) involved. These include the availability of: (1) molecular oxygen; (2) a source of electrons and accessory proteins used to deliver electrons to the mixed function oxydases CYP27A1 and CYP27B1 (i.e. NADPH-ferredoxin reductase and ferredoxin); (3) substrates (vitamin D3 and 25OHD3) localized at the enzyme’s catalytic sites; and possibly (4) intracellular vitamin D binding proteins which can regulate synthesis of 1α,25(OH)2D3 (44).

Circulating 25OHD – a substrate for further metabolism in epidermal keratinocytes?

The cutaneous metabolism of circulating 25OHD3 to 1α,25(OH)2D3 should be reconsidered as the amount of free 25OHD3 that permeates the cell membrane of epidermal keratinocytes is maybe too low to induce formation of sufficient amounts of 1α,25(OH)2D3. 25-Hydroxyvitamin D3 is very tighly bound to DBP (Kd = 5 × 10−8 m) in circulating blood (45). Due to this tight binding and the high plasma concentration of DBP (0.3–0.5 mg/ml) virtually all 25OHD3 molecules in the circulatory system are present in a complex with DBP. Only approximately 0.03% of the metabolite is found in free form (46). According to the free hormone hypothesis (47), steroids including 1α,25(OH)2D3 and 25OHD3 enter target cells by passive diffusion. It seems to be unlikely that epidermal keratinocytes can incorporate 25OHD × DBP or 1α,25(OH)2D x DBP complexes in vivo by megalin/cubilin-mediated endocytosis like mammary cells (48) or renal proximal tubule cells (49). The deeper layers of the epidermis are not vascularized, which additionally impairs the passage of 25OHD from blood to epidermal keratinocytes.

Specifics of the cutaneous vitamin D3 pathway

Human keratinocytes have an autonomous vitamin D3 pathway (6–9,38,50). This pathway includes UVB-induced synthesis of vitamin D3 and its stepwise hydroxylation to calcitriol (Fig. 1). A five-step inactivation pathway from calcitriol to calcitroic acid in epidermal keratinocytes is attributed to the catabolic enzyme CYP24A1, which is transcriptionally induced by the action of calcitriol in a very sensitive manner (35,51). It has been shown that already picomolar concentrations of free 1α,25(OH)2D3 can induce the CYP24A1 in cultured keratinocytes (35). The physiological importance of a second catabolic pathway which includes the conversion of 1α,25(OH)2D3 to the A-ring diastomer 1α,25(OH)2D-3epi-D3 is less clear (52).

Addition of exogenous 1α,25(OH)2D3 at supraphysiological doses (12 nm) to cultured keratinocytes reduce keratinocyte 7-DHC/vitamin D3 levels, suggesting that calcitriol regulates vitamin D3 production via an intracellular feedback loop (53). Additional endocrine factors including Ca2+, hydrocortison, and EGF seem to regulate the production of vitamin D3 in human keratinocytes. Some steroidal hormones (testosterone, androstendione, progesterone, oestradiol and 11-deoxycorticosterone) can potently inhibit the CYP27B1 of the vitamin D3 pathway in human keratinocytes (54). Moreover, It is well known that the epidermis is a site of high androgen production.

In vitro investigations have shown that dermal fibroblasts express one of the potential 25-hydroxylases (CYP27A1), but not the 1α-hydroxylase (CYP27B1) (Fig. 1). Therefore, fibroblasts might play an important role in the supply of calcitriol precursors (vitamin D3 and 25OHD3) for keratinocytes and possibly for circulating blood, too (55).

Conclusions, open questions and hypotheses

The main steps of the cutaneous vitamin D3 pathway are well known. Several subleties and fine tuning mechanisms of this pathway wait for final clarifying, yet. That implies questions: Why do some people exhibit a low vitamin D status despite abundant sun exposure? (56) Why do chronic hemodialysis patients exhibit defective photoproduction of vitamin D3, despite normal epidermal content of the substrate 7-DHC? (57). What endogenous and exogenous factors including drugs affect the cutaneous vitamin D3 pathway? Other questions arise: Are there interactions between cutaneous calcitriol production or external vitamin D analogs and other hormones/cytokines within the skin? The physiological role of the cutaneous vitamin D3 metabolism to calcitriol remains still unknown. Of paramount interest is the role of this pathway in the UVB-(and PUVA-photo(chemo)therapy? (58,59)) of psoriasis. Finally, it is noteworthy that strict sun protection combined with low nutritional intake of vitamin D over a long time does not result in absolute vitamin D3 deficiency and absence of 25OHD in the circulation. This fact implies the question: Can vitamin D3 be produced in ‘emergency situations’ by UVB-independent pathway(s)? Four nonphotochemical enzymatic mechanisms have been proposed as possible reactions for the generation of vitamin D3 in appropriate biological systems (60). There is, however, presently no experimental evidence to support their existence.

Hormonal effects of calcitriol in the skin

The particular role of VDR in gene activation

Skin cells (keratinocytes, epithelial cells of the epidermal appendages, melanocytes, Langerhans cells, CD11b+ macrophages, CD3+ T-lymphocytes and dermal fibroblasts) express VDR (10,61), an absolute prerequisite for regulation of genomic effects of calcitriol and other synthetic analogs. The VDR activates transcription by binding to vitamin D response elements (VDREs) within the promoter of vitamin D reponsive genes either as a homodimer (62,63) or a heterodimer with retinoid acid X receptor-α (RXR) (63) or thyroid hormone receptor (TR) (64,65). VDR RXR heterodimers form more stable complexes on VDERs as compared to VDR homodimers. Therefore, it has been generally considered that VDR RXR heterodimers play a dominating role in mediating calcitriol action. Suprisingly, it was shown that the ligand-dependent interaction of VDR with several coactivators (SRC-1 and TRAM-1) facilitates homodimer formation and that VDR homodimers may mediate ligand-induced transactivation, as well as VDR RXR heterodimers (66). Other studies using TR provided similar results and indicated that TR may function through its liganded homodimer (66,67). In contrast, it was demonstrated in another study that VDR diplays DNA binding and transactivation as a heterodimer with RXR but not with the TR (68).

That implies that RXR/TR selective retinoids and thyroid hormones, respectively, may influence targeting of calcitriol, in addition to the RXR and TR responsive ones. On the other hand, calcitriol and other nuclear hormones may also regulate RXR and TR responsive genes. Hence, combinations of RXR selective retinoids, thyroid hormones and calcitriol/vitamin D analogs might excel the expected therapeutical result and reduce unwanted side-effects/toxicity of each single agent (69).

Interestingly, selected transcriptional effects of VDR may be uncoupled from the 1α,25(OH)2D3 ligand in keratinocytes (70). It has been demonstrated that VDR activates the 24-hydroxylase (CYP24A1) promoter independently of 1α,25(OH)2D3 in primary keratinocytes (70). Overexpression of VDR in keratinocytes increases not only CYP24A1 expression but also a number of markers of differentiation such as keratin 1, loricrin and filaggrin whereas suppression of VDR expression markedly reduces the expression of these markers in the absence of 1α,25(OH)2D3 (71).

Finally, the functions of VDR are not limited to the binding to VDREs and the regulation of gene expression. VDR has also been found to bind β-catenin, a key transcriptional factor in the Wnt pathway. This pathway plays a role in a number of malignancies, because it can induce hyperproliferation. VDR binds to, and thus blocks the transcriptional activity of β-catenin (72). The ability of VDR to bind β-catenin may account for at least some of the antiproliferative actions of 1α,25(OH)2D3 in a variety of tissues including skin cancer.

Of note, UVB which is essential for the induction of the cutaneous vitamin D3 pathway suppresses VDR expression in cultured keratinocytes in vitro (73) and retinoid acid receptors (RAR-γ and RXR-α) in human skin in vivo (74). However, observed effects of UV radiation in human skin were oppositional in terms of the retinoid and calcitriol responsiveness: UV irradiation caused an almost complete loss of retinoid acid induction of distinct RAR/RXR target genes but did not affect calcitriol-induction of the VDR/RXR-regulated gene CYP24A1 (74). Thus, in contrast to the observed impairment of retinoid responsiveness, UV radiation had no apparent effect on 1α,25(OH)2D3-responsiveness in human skin.

Conclusions, open questions and hypotheses

It is well accepted that calcitriol exerts a number of genomic and non-genomic effects in keratinocytes. However, a more detailed dissection of the pathways leading to 1α,25(OH)2D3-independent VDR transactivation would be of utmost interest. A clear separation between ligand-dependent and ligand-independent VDR-mediated processes appears to be necessary with regard to genomic effects originally imputed to calcitriol. It also remains to be clarified whether lack of VDR indeed entailes deleterious effects on skin function contributing to skin photo-aging and carcinogenesis (75).

Targets of 1α,25(OH)2D3 in keratinocytes

A vast number of genes in primary human keratinocytes and squamous carcinoma cell lines are regulated by calcitriol and its analogs (76–78). Important candidate target genes related to 1α,25(OH)2D3-induced effects on cellular growth, differentiation and inflammation/woundhealing in keratinocytes are listed in Table 1.

Table 1.   Regulatory activities of 1α,25(OH)2D3 on genes related to growth, differentiation and inflammation/woundhealing in keratinocytes
Effect of 1α,25(OH)2D3 onmRNAProteinVDRERef.
Proliferation-associated genes
c-myc[DOWNWARDS ARROW]  (79,80)
c-fos[UPWARDS ARROW] +(81)
Cyclin D1[DOWNWARDS ARROW]  (77)
TGF-β1/2[UPWARDS ARROW][UPWARDS ARROW]+(β2)(82,83)
p21WAF1/CIP1[UPWARDS ARROW][UPWARDS ARROW]+(79)
p27KIP1 [UPWARDS ARROW] (79,84)
PTHrP[DOWNWARDS ARROW][DOWNWARDS ARROW] (85)
EGF [UPWARDS ARROW] (86)
GADD45α[UPWARDS ARROW]  (78,87)
Insulin like GF[DOWNWARDS ARROW]  (88)
IGFBP-3[UPWARDS ARROW]  (89)
17β-OH-Steroiddehydrogenase[UPWARDS ARROW][UPWARDS ARROW] (90)
IEX-1[DOWNWARDS ARROW][DOWNWARDS ARROW] (91–93)
TRPV6[UPWARDS ARROW][UPWARDS ARROW] (87,94)
Differentiation related genes
Involucrin[UPWARDS ARROW][UPWARDS ARROW]+(11)
Transglutaminase I[UPWARDS ARROW][UPWARDS ARROW] (11)
u- and t-plasminogen activator[DOWNWARDS ARROW][DOWNWARDS ARROW]+(95)
PLC (β, γ, δ)[UPWARDS ARROW][UPWARDS ARROW]+(γ1)(96–98)
Integrin α7B[UPWARDS ARROW]  (87)
Peptidylarginine deiminases[UPWARDS ARROW]  (77)
Kallikrein[UPWARDS ARROW]  (77)
Serine proteinase inhibitors[UPWARDS ARROW]  (77)
PPARγ[UPWARDS ARROW][UPWARDS ARROW] (99)
Caspase-14 (psoriatic skin)[UPWARDS ARROW]  (100)
Inflammation and woundhealing-related genes
TNFα[UPWARDS ARROW][UPWARDS ARROW]+(101,102)
IL-1α [DOWNWARDS ARROW] (103)
IL-6[DOWNWARDS ARROW][DOWNWARDS ARROW] (76)
IL-8 [DOWNWARDS ARROW] (103,104)
IL-10 (IL-10 receptor)[UPWARDS ARROW]([UPWARDS ARROW])  (105)
PDGF [UPWARDS ARROW] (106)
RANTES [DOWNWARDS ARROW] (104)
i-NOS  +(107)
5-Lox  +(107)
CAMP/cathelicidin[UPWARDS ARROW][UPWARDS ARROW]+(108,109)
DEFB2/Defensin 2[UPWARDS ARROW] +(109)

Regulation of cell functions of keratinocytes by 1α,25(OH)2D3

Growth and differentiation

Low concentrations of 1α,25(OH)2D3 stimulate growth of keratinocytes in vitro, whereas higher doses (≥10−8 m) inhibit keratinocyte proliferation (110). The former effect of calcitriol in keratinocytes may be based on enhancement of the growth-promoting activity of EGF ligands (86). Consistently, pharmacological doses of calcitriol and vitamin D analogs are effective in the treatment of the hyperproliferative skin disease psoriasis.

Although the mechanisms that underlie the antiproliferative and prodifferentiating effects of vitamin D analogs on keratinocytes are far from being understood, it is well known that these effects are largely of genomic nature and are mediated by VDR as well as several coactivators (71,111,112). VDR expression is associated with undifferentiated, proliferating keratinocytes, whereas RXR-α expression appears to be related to the differentiated phenotype. Thus, proliferating and differentiating keratinocytes may be differentially affected by active vitamin D compounds (113).

Growth inhibitory effects of biological inactive vitamin D3 on cultured keratinocytes?

Vitamin D3 by itself is not only biologically inactive but also nearly insoluble in aqueous culture media because of its extreme lipophilic character. This problem can be circumvented by adding exogenous bovine serum albumin (BSA) to the culture medium which improves the solubility of vitamin D3 and, therefore, its availability for the metabolism to 1α,25(OH)2D3 in cultured keratinocytes (7). BSA has, however, the disadvantage of changing the cell morphology and increasing cell aggregation (data not shown). It is more convenient to apply Pluronic® F127, a bifunctional triblock copolymer surfactant (poloxamer) composed of polyoxyethyle-ene-polyoxypropylene-polyoxyethylene (MW = 12.500) (114,115), to improve of the solubility of vitamin D3 in aqueous culture media. This agent considerably improves the uptake of vitamin D3 by keratinocytes without adverse effects on cell viability. Consistently, the conversion rate of vitamin D3 (1 μm) to 1α,25(OH)2D3 is 1,7 fold higher in the presence of Pluronic® F127 (100 μg/ml medium) than in the presence of BSA (10 mg/ml medium) (data not shown). The inhibition of proliferation of keratinocytes at increasing concentrations of vitamin D3 (250, 500, 1000 nm) in presence of Pluronic® F127 correlates well with the production of calcitriol (Fig. 2a), and highly significant inhibition of 3H-thymidine incorporation can be observed at 250 nm vitamin D3 (equivalent to 114 fmol calcitriol per well) already. In contrast, both the conversion rate of vitamin D3 to calcitriol and incorporation of 3H-thymidine in cellular DNA are clearly delayed in the absence of Pluronic® F127 (Fig. 2b). There was neither inhibition of cell growth in the absence of vitamin D3 nor in the presence of Pluronic® F127 alone (Fig. 2c).

image

Figure 2.  Inhibition of keratinocyte growth by 1α,25(OH)2D3 formed after metabolization of exogeneous added biologically inactive vitamin D3. Keratinocytes were seeded in culture dishes (5 × 104 cells/dish, diameter: 32 mm) and cultivation was carried out in 1.5 ml KGM (0.15 mm Ca2+) at 37°C in a humidified atmosphere of 5% CO2 in air. (a) Three days after seeding (degree of confluency: 40–60%) KGM was supplemented with vitamin D3 (final concentration: 250, 500 and 1000 nm) and Pluronic® F127 (100 μg/ml KGM) that was solubilized in ethanol (final concentration of ethanol: 0.5%). Incorporation of 3H-thymidine as percent of control and formation of calcitriol in keratinocytes was determined 3 days after addition of vitamin D3; (b) KGM was supplemented with vitamin D3 (final concentration: 250, 500 and 1000 nm) without Pluronic® F127; (c) Control experiments were carried out in absence of vitamin D3. The calcitriol formed was extracted and determined as described previously (7). The effect of calcitriol on DNA synthesis was determined by incorporation of [3H]-thymidine in cellular DNA. Cells were pulse-labeled with 1 μCi of [methyl, 1′,2′-3H]thymidine (126 Ci/mmol, Amersham) for 3 h. Cultures were washed three times with PBS and twice with 10% (w/v) TCA. Cells were solubilized with 1 M NaOH and radioactivity was determined – with a scintillation counter. Concentrations of calcitriol (fmol/well) and 3H-thymidine incorporation (percent of control) are shown as mean ± SD of four independent experiments (Student–Newman–Keuls multiple comparisons test: ns not significant, *P < 0.05 significant, **P < 0.01 very significant, ***P < 0.001 extremely significant versus untreated control).

Download figure to PowerPoint

These findings confirm and extend results of Chen et al. (116) and Popadic et al. (117), who demonstrated that vitamin D3 is effective in inhibiting 3H-thymidine incorporation into DNA of cultured human keratinocytes at concentrations between 10−8 and 10−6 m as well as 1.25 – 5.0 × 10−6 m, respectively. Our results provide the first experimental evidence that the antiproliferative effect of vitamin D3 significantly correlates with the amount of hormonally active calcitriol intracellularly produced by hydroxylation of the biologically inactive substrate vitamin D3. Thus, our findings indicate that cutaneous metabolism of vitamin D3 to calcitriol may contribute to the normalization of the hyperproliferative condition of keratinocytes in vitro, and possibly in psoriatic skin, too. This hypothesis is supported by the fact that the UVB-induced synthesis of vitamin D3 is unimpaired in psoriatic individuals (27). It remains to be clarified, however, whether enzymatic conversion of vitamin D3 to calcitriol is unimpaired in psoriatic skin, too. Notably, in psoriatic keratinocytes 3H-1α,25(OH)2D3 is catabolized approximately 2.5 times faster than in normal keratinocytes (118). This finding suggests for a disturbed balance between UVB-induced synthesis of calcitriol and its catabolism in psoriatic keratinocytes.

Conclusions, open questions and hypotheses

Biological effects of calcitriol in keratinocytes and other skin cells require a sufficient intracellular level of this hormon. It is not clear from in vitro trials whether the extracellular calcitriol concentration induces an identical intracellular concentration. Concentrations of calcitriol created within keratinocytes may succeed the circulating concentration by far (8). Consistently, we have demonstrated that biologically inactive vitamin D3 developes antiproliferative activity on keratinocytes in vitro, however, only after its metabolization to 1α,25-dihydroxyvitamin D3. It has to be verified now, whether this growth-inhibitory effect of vitamin D3in vitro can also be observed in psoriatic skin. In addition, it would be of considerable interest whether cutaneous calcitriol generated in psoriatic skin after UVB exposure develops a growth-inhibitory effect on proliferating epidermal keratinocytes similar to topical applicated calcitriol.

Apoptosis

Physiological concentrations of calcitriol do not initiate apoptosis in cultured keratinocytes, but rather, cause resistance against proapoptotic ceramides, UV radiation and tumor necrosis factor-α (TNF-α) (119). The cytoprotective/antiapoptotic effect of calcitriol is seemingly linked to the generation of sphingosine-1-phosphate (119). In contrast, pharmacological concentrations of calcitriol (≥10−6 M) exert a proapoptotic effect on keratinocytes.

Conclusions, open questions and hypotheses

Regulatory effects of calcitriol on both cellular growth and apoptosis are characterized by a dual mechanism of action. Low calcitriol concentrations stimulate cell proliferation and suppress apoptosis; higher (pharmacological) concentrations dose-dependently decrease proliferation and initiate apoptosis of keratinocytes. The underlying cause of this different behavior is presently unknown.

Skin appendages: targets for cutaneous calcitriol?

Sebaceous glands

It was shown by Sato et al. (120) that calcitriol suppresed the accumulation of intracellular lipid droplets in hamster sebocytes whereas the cellular DNA content was not altered. Hence, 1α,25(OH)2D3 may be involved in the suppressive regulation of lipogenesis in hamster sebocytes and possibly in human sebocytes, too (120). More recently, it was reported that sebocytes express functional cathelicidin antimicrobial peptide (CAMP) which acts as an agent against propionibacterium acnes (121). This result might be of prime importance because strong upregulation of cathelicidin synthesis at the mRNA- and protein level by calcitriol and calcipotriol (MC903) has been found in human keratinocytes in vitro and in vivo (108,122). Thus, it seems entirely possible that calcitriol also regulates cathelicidin production in sebocytes.

Recently, a study has demonstrated that calcitriol dose-dependently suppressed the growth of the cell line SZ95, derived from human sebaceous gland (123,124) The mRNA of VDR, CYP27A1, CYP27B1 and CYP24A1 were stronly expressed in these cells (123). Hence, biochemical prerequisites for local synthesis of 1α,25(OH)2D3 from vitamin D3 or 25OHD3 and signal transduction of active vitamin D3 are available in these cells.

Conclusions, open questions and hypotheses

Metabolism of vitamin D3 and 25OHD3 to 1α,25(OH)2D3 in human sebocytes might be of relevance to both regulation of growth and production of antimicrobial peptides in these cells. On the other hand, it is well known that UVB radiation necessary for photosynthesis of vitamin D3 worsens acne. The question arises: Does the vitamin D3 pathway properly work in lesional skin of acne patients?

Hair follicle

Originally, it was assumed that 1α,25(OH)2D3 plays a fundamental role in hair follicle biology. This is probably wrong and should be reconsidered. The control of hair follicle development and cyling depends on the VDR expression; the presence of its ligand 1α,25(OH)2D3 is apparently not necessary (125,126). VDR expression in the hair follicle is increased during late anagen (hair growth phase), and catagen (regression phase), correlating with decreased proliferation and increased differentiation of the follicle keratinocytes. It is assumed, however, that repressive effects of the VDR on the hair cycle involve additional co-modulators or factors (127).

More recently the corepressor hairless (Hr) has been found in the epidermis and brain. Hr binds to the VDR in absence of 1α,25(OH)2D3 and blocks its ability to stimulate gene transcription (128). The ability to regulate the transcriptional activity of VDR suggests that such interactions are involved in hair follicle cycling. Loss of Hr just like loss of VDR results in alopecia. Interaction between these two molecules may control normal hair follicle cycling. Lack of VDR results in increased expression of Hr suggesting that VDR may act directly or indirectly to regulate Hr expression (129).

Results of Li et al. (130,131) have demonstrated that the retinoic acid receptor RXR-α plays a key role in anagen initiation during the hair follicle cyle. RXR-α ablation results in epidermal interfollicular hyperplasia with keratinocyte hyperproliferation and aberrant terminal differentiation, accompanied by an inflammatory reaction of the skin. Hence, RXR-α/VDR heterodimers play a major role in controlling hair cycling.

Data obtained from animal models indicate that topical calcitriol may protect against chemotherapy-induced alopecia (132). On the other hand, it was found that calcitriol treatment results in accelerated and qualitative improved hair regrowth but does not prevent chemotherapy-induced alopecia (133,134).

Conclusions, open questions and hypotheses

Hair follicles may be targets of cutaneos calcitriol. On the other hand, the control of hair follicle development and cyling needs particularly unliganded VDR; the presence of its ligand 1α,25(OH)2D3 is seemingly not necessary. Both Hr and VDR are required for normal hair follicle cyling. Whether Hr acts as a corepressor for ligand-independent actions of VDR in hair follicles has yet to be determined.

Immunomodulating effects of calcitriol in the skin

More recently, it was shown that both dendritic cells (DCs) and cocultures of DCs and T cells efficiently metabolize the biologically inactive prohormone vitamin D3 to hormonally active calcitriol, providing a mechanism for the local regulation of T cell ‘epidermotropism’ (135). Calcitriol induces the transcription and surface expression of the skin T-cell-associated chemokine receptor CCR10, conferring attraction to the epidermal chemokine CCL27 to T cells (135). It has been demonstrated that a single topical application of a physiological relevant amount of 1α,25(OH)2D3 to the shaved dorsal skin of mice enhances the suppressive capacity of CD4+ CD25+ regulatory T cells in the draining lymph nodes (136). Calcitriol inhibits differentiation and maturation of DCs and induces a phenotype that promotes tolerance and inhibits immunity after stimulation with antigen (137,138). Calcitriol and vitamin D analogs suppress IgE-production in vitro and IgE-mediated reactions in the skin (139,140). On the other hand, it has been reported that topical application of calcitriol or of its low-calcemic analog calcipotriol induces the expression of the cytokine thymic stromal lymphopoietin (TSLP) in the skin of mice resulting in an atopic dermatitis-like syndrome, which is known from transgenic mice overexpressing TSLP (141). Of note, TSLP is also produced in epidermal keratinocytes of AD patients (142). It is well known that most common side effect of topical treatment of psoriasis with calcipotriol is skin irritation (red, dry, and itchy skin) (143). Accordingly, the data of Li et al. (141) have shown that administration of calcitriol may exacerbate AD and very likely, asthma by promoting expression of TSLP in skin and lungs. Consistently, it has been concluded from these results that topical administration of calcitriol antagonists might be beneficial for treatment of AD.

Conclusions, open questions and hypotheses

Immunomodulating effects of calcitriol and its analogs on keratinocytes as well as monocytes, macrophages, T lymphocytes and, in particular DCs, have been convincingly demonstrated. However, light and shade are close together from the therapeutic point of view. Novel vitamin D anlogs are needed for highly specific and effective regulation of immunological processes. The role of the cutaneous vitamin D3 pathway is not clear yet. It also remains to be seen whether the so called vitamin D hypothesis can explain increased incidence of astma and allergies (144).

Calcitriol induces antimicrobial activity in human skin

There is convincing evidence that 1α,25(OH)2D3 and its analog calcipotriol directly regulate antimicrobial peptide gene expression in human skin, revealing the potential of these compounds for the treatment of opportunistic infections (122,145,146). The promoters of the human cathelicidin antimicrobial peptide (CAMP) and defensin 2 (defB2) genes contain consensus VDRE that mediate 1α,25(OH)2D3-dependent gene expression (108).

Using microdialysis, we have demonstrated that irradiation with UVB induces the synthesis of calcitriol in human skin (38,50). Recently, it was shown by Mallbris et al. (147) that under comparable experimental conditions both the VDR and the precursor of the antimicrobial peptide cathelicidin (CAMP) (also known as hCAP18, LL-37 or FALL-39), were significantly upregulated. The effect was not observed following UVA exposure, ruling out the cutaneous synthesis of vitamin D3 and calcitriol. In vitro, both 1α,25(OH)2D3 and 25OHD3 exhibited stimulatory activity on expression of CAMP (122). Induction of CAMP expression in keratinocytes and monocytes is mediated by Toll-like receptors (148,149). A link between the cutaneous vitamin D3 pathway and induction of CAMP might be of importance in reduction of inflammation, wound repair and healing of burns (146,148–150). AD also has been associated with depressed expression of LL-37; therefore, an appropriate therapeutical use of vitamin D analogs and/or UVB should be considered (146). On the other hand, this strategy would be conflicting because application of these agents might lead to exacerbation of AD and possibly astma by promoting expression of TSLP in skin and lungs (141).

Conclusions, open questions and hypotheses

Topical treatment of human skin with 1α,25(OH)2D3 has been shown to enhance cathelicidin peptide expression. However, molecular mechanisms controlling the expression of CAMP are still poorly understood. The capacity of 1α,25(OH)2D3 to alter the antimicrobial function of keratinocytes and other skin cells is unknown yet. Furthermore, it is not clear why cathelicidin production is initiated upon injury an incident not associated with alterations in vitamin D signalling. The relevance of AMP’s for several skin diseases like AD, psoriasis and infectious skin diseases with bacterial, viral or fungal background has to be clarified. It is attractive to speculate that acute exposure of the skin to sunlight and subsequent activation of the cutaneous vitamin D3 pathway might turn the immune balance in favor of innate immune defense.

The cutaneous vitamin D3 pathway and skin cancer

UV radiation, essential for triggering of the cutaneos vitamin D3 pathway, is a well-documented carcinogen, indisputably linked to the current continued increased rate of skin cancer (151). These cancers include melanomas and two types of malignant keratinocytes: basal-cell carcinomas (BCC) and squamous – cell carcinomas (SCC). 1α,25(OH)2D3 in turn stimulates the differentiation of epidermal keratinocytes, raising the hope that 1α,25(OH)2D3 may prevent the development of malignancies in these cells (98). In contrast to normal cells, malignant transformation may cause a resistance to 1α,25(OH)2D3 (152). SCCs fail to respond to the prodifferentiating effects of 1α,25(OH)2D3 (153,154). Considered for itself, this is suprising because these cells have normal expression of VDR and normal binding of VDR to vitamin D response elements. However, they overexpress coactivator DRIP205 such that the p160/SRC coactivator complex is blocked from binding to VDR (98,155).

Conclusions, open questions and hypotheses

Unfortunately, we do not exactly know how malignant cells can evade normal growth-arresting and prodifferentiating signals. By all appearances, clearing up of molecular alterations and disturbed control mechanisms underlying skin cancer will take some time for final clarification.

Skin protecting effects of calcitriol

Skin photocarcinogenesis is caused largely by DNA damage, most importantly mutations at sites of incorrectly repaired DNA photoproducts, of which the most common are the cyclobutane pyrimidine dimers (CPDs) (156). It has been reported that 1α,25(OH)2D3 protects primary human keratinocytes against the induction of CPDs by UVB (157,158). When applicated topically to mouse skin, calcitriol or analogs decrease UV-induced DNA damage, sunburn cells and immune suppression (159). Interestingly, 1α,25(OH)2D3 exerts its photoprotective effects via the rapid non-genomic pathway (160). Moreover, calcitriol produced in the skin may enhance UV-induced p53 protein expression and suppress nitric oxide (NO) products resulting in increased DNA repair (161). Other studies have demonstrated genoprotective effects of calcitriol or its analogs against accumulation of mutations which underly the cellular transformation and cancer progression (162,163).

Conclusions, open questions and hypotheses

It is tempting to speculate from these findings that the UVB-induced cutaneous production of calcitriol represents a hormonal feedback mechanism that protects the skin from the hazardous effects of solar UV-radiation. Therefore, endogenous calcitriol or active vitamin D compounds may represent promising candidates for the chemoprevention of UVB-induced skin cancer.

Outlook

  1. Top of page
  2. Abstract
  3. Introduction
  4. Outlook
  5. Acknowledgements
  6. References

A broad variety of skin diseases such as psoriasis, vitiligo, ichthyosis, Darier’s disease, ILVEN, lichen amyloides, localized scleroderma, morphea, bullous pemphigoid, acanthosis nigricans, acrodermatitis continua of Hallopeau, erythema annulare centrifugum, Grover’s disease and other disorders can be more or less improved by application of calcitriol or vitamin D analoga (164–166). Until now, however, therapeutical usage of calcitriol and its analogs in the dermatology is rather limited and only established for treatment of psoriasis. It remains to be seen whether calcitriol and other synthetic vitamin D analogs are sufficiently effective for clinical treatment of nonpsoriatic skin diseases, malignancies included (167,168). It should also be mentioned that calcipotriol a well known antipsoriatic vitamin D analog has been found to have no therapeutical effect in the following nonpsoriatic diseases: alopecia totalis, alopecia areata, acne vulgaris, ichthyosis bullosa of Siemens, palmoplantar keratoderma, and keratosis pilaris (Darier’s disease) (165).

We conclude from our own and other studies that locally produced 1α,25(OH)2D3 may in fact suppress growth and induces differentiation of keratinocytes (34,116,117,169). Altogether, our knowledge about regulation of cellular functions by the cutaneous vitamin D3 pathway or by vitamin D analogs is insufficient yet. It is necessary to characterize the underlying signalling pathways and continue with the identification of further calcitriol-responsive genes in the skin. From the therapeutical point of view, the inhibition of the enzymatically regulated catabolism of calcitriol and its analogs by selectively acting CYP24A1 inhibitors remains an interesting therapeutical approach (170).

Acknowledgements

  1. Top of page
  2. Abstract
  3. Introduction
  4. Outlook
  5. Acknowledgements
  6. References

I would especially like to thank Dr Wolfgang Eicheler (Clinic of Radiotherapy, Technische Universität Dresden) for critical proof-reading the paper. This paper was gracefully supported by Prof. Dr Michael Meurer (Professor and Chairman, Department of Dermatology, Technische Universität Dresden).

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Outlook
  5. Acknowledgements
  6. References
  • 1
    Holick M F, MacLaughlin J A, Clark M B, Holick S A, Potts J T. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 1980: 210: 203205.
  • 2
    Reichrath J, Holick M F. Clinical Utility of 1,25-dihydroxyvitamin D3 and its analogs for the treatment of psoriasis and other skin diseases. In: HolickM F, ed. Vitamin D. Physiology, Molecular Biology and Clinical Applications. New Jersey: Humana Press Totowa, 1999: 357374.
  • 3
    Lehmann B, Querings K, Reichrath J. Vitamin D and skin: new aspects for dermatology. Exp Dermatol 2004: 13 (Suppl 4): 1115.
  • 4
    Holick M F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006: 81: 353373.
  • 5
    Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extrarenal 1α-hydroxylase in the classical and nonclassical actions of 1α,25-dihydroxyvitamin D3. Semin Dial 2007: 20: 316324.
  • 6
    Lehmann B, Rudolph T, Pietzsch J, Meurer M. Conversion of vitamin D3 to 1α,25-dihydroxyvitamin D3 in human skin equivalents. Exp Dermatol 2000: 9: 97103.
  • 7
    Lehmann B, Genehr T, Knuschke P, Pietzsch J, Meurer M. UVB-induced conversion of 7-dehydrocholesterol to 1α,25-dihydroxyvitamin D3 in an in vitro human skin equivalent model. J Invest Dermatol 2001: 117: 11791185.
  • 8
    Schuessler M, Astecker N, Herzig G, Vorisek G, Schuster I. Skin is an autonomous organ in synthesis, two-step activation and degradation of vitamin D3: CYP27 in epidermis completes the set of essential vitamin D3-hydroxylases. Steroids 2001: 66: 399408.
  • 9
    Vantieghem K, Kissmeyer A M, De Haes P, Bouillon R, Segaert S. UVB-induced production of 1,25(OH)2D3 production and vitamin D activity in human keratinocytes pretreated with a sterol delta 7 reductase inhibitor. J Cell Biochem 2006: 98: 8192.
  • 10
    Milde P, Hauser U, Simon T et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 1991: 97: 230239.
  • 11
    Bikle D D, Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocr Rev 1993: 14: 319.
  • 12
    Chromsystems, Diagnostics by HPLC. Arbeitsvorschrift für die HPLC-Bestimmung 25-OH-Vitamin D3/D2 im Serum/Plasma. AV 38.038 VITD3/D2 D Apr 2007 V1, 9.
  • 13
    Matsuoka L Y, Wortsman J, Haddad J G, Hollis B W. In vivo threshold for cutaneous synthesis of vitamin D3. J Lab Clin Med 1989: 114: 301305.
  • 14
    Holick M F, MacLaughlin J A, Doppelt S H. Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science 1981: 211: 590593.
  • 15
    Norman A W. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am J Clin Nutr 1998: 67: 11081110.
  • 16
    Axelson M. Occurrence of isomeric dehydrocholesterols in human plasma. J Lipid Res 1991: 32: 14411448.
  • 17
    Bekemeier H. Vitamin D der Haut. Int Z Vitaminforsch 1966: 10: 80110.
  • 18
    Davie M, Lawson E M. Assessment of plasma 25-hydroxyvitamin D response to ultraviolet irradiation over a controlled area in young and elderly subjects. Clin Sci 1980: 58: 235242.
  • 19
    Obi-Tabot E T, Tian X Q, Chen T C, Holick M F. A human skin equivalent model that mimics the photoproduction of vitamin D3 in human skin. In Vitro Cell Dev Biol Anim 2000: 36: 201204.
  • 20
    MacLaughlin J, Holick M F. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985: 76: 15361538.
  • 21
    Holick M F, Matsuoka L Y, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet 1989: 2: 11041105.
  • 22
    Clemens T L, Adams J S, Henderson S L, Holick M F. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982: 9: 7476.
  • 23
    Chen T C, Chimeh F, Lu Z et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys 2007: 460: 213217.
  • 24
    Webb A R, Kline L, Holick M F. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988: 67: 373378.
  • 25
    Webb A R. Who, what, where and when-influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 2006: 92: 1725.
  • 26
    Matsuoka L Y, Wortsman J, Hanifan N, Holick M F. Chronic sunscreen use decreases circulating concentrations of 25-hydroxyvitamin D. A preliminary study. Arch Dermatol 1988: 124: 18021804.
  • 27
    Matsuoka L Y, Wortsman J, Haddad J G, Hollis B W. Cutaneous formation of vitamin D in psoriasis. Arch Dermatol 1990: 126: 11071108.
  • 28
    Holick M F, Matsuoka L Y, Wortsman J. Regular use of sunscreen on vitamin D levels. Arch Dermatol 1995: 131: 13371339.
  • 29
    Farrerons J, Barnadas M, Rodríguez J et al. Clinically prescribed sunscreen (sun protection factor 15) does not decrease serum vitamin D concentration sufficiently either to induce changes in parathyroid function or in metabolic markers. Br J Dermatol 1998: 139: 422427.
  • 30
    Sollitto R B, Kraemer K H, DiGiovanna J J. Normal vitamin D levels can be maintained despite rigorous photoprotection: six years’ experience with xeroderma pigmentosum. J Am Acad Dermatol 1997: 37: 942947.
  • 31
    Marks R, Foley P A, Jolley D, Knight K R, Harrison J, Thompson S C. The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. Arch Dermatol 1995: 131: 415421.
  • 32
    Adams J S, Clemens T L, Parrish J A, Holick M F. Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N Engl J Med 1982: 306: 722725.
  • 33
    Tian X Q, Chen T C, Matsuoka L Y, Wortsman J, Holick M F. Kinetic and thermodynamic studies of the conversion of previtamin D3 to vitamin D3 in human skin. J Biol Chem 1993: 268: 1488814892.
  • 34
    Matsumoto K, Azuma Y, Kiyoki M, Okumura H, Hashimoto K, Yoshikawa K. Involvement of endogenously produced 1,25-dihydroxyvitamin D3 in the growth and differentiation of human keratinocytes. Biochim Biophys Acta 1991: 1092: 311318.
  • 35
    Bikle D D, Gee E. Free, and not total 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes. Endocrinology 1989: 124: 649654.
  • 36
    Zehnder D, Bland R, Stewart P M, Hewison M. Analysis of the tissue distribution of 1α-hydroxylase identifies novel extra-renal sites for the synthesis of 1,25-dihydroxyvitamin D3. J Endocrinol 2000: 164: P1.
  • 37
    Hewison M, Burke F, Evans K N et al. Extrarenal 25-hydroxyvitamin D3 -1α-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 2007: 103: 316321.
  • 38
    Lehmann B, Meurer M. Extrarenal sites of calcitriol synthesis: the particular role of the skin. Recent Results Cancer Res 2003: 164: 135145.
  • 39
    Bikle D D, Nemanic M K, Gee E, Elias P. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. J Clin Invest 1986: 78: 557566.
  • 40
    Gottfried E, Rehli M, Hahn J, Holler E, Andreesen R, Kreutz M. Monocyte derived cells express CYP27A1 and convert vitamin D3 into its active metabolite. Biochem Biophys Res Commun 2006: 349: 209213.
  • 41
    Tokar E J, Webber M M. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1 in human prostate epithelial cells. Clin Exp Metastasis 2005: 22: 265273.
  • 42
    Tokar E J, Webber M M. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis 2005: 22: 275284.
  • 43
    Ichikawa F, Sato K, Nanjo M et al. Mouse primary osteoblasts express vitamin D3 25-hydroxylase mRNA and convert 1α-hydroxyvitamin D3 into 1α,25-dihydroxyvitamin D3. Bone 1995: 16: 129135.
  • 44
    Wu S, Chun R, Gacad M A et al. Regulation of 1,25-dihydroxyvitamin D synthesis by intracellular vitamin D binding protein-1. Endocrinology 2002: 143: 41354138.
  • 45
    Haddad J G. Plasma vitamin D-binding protein (Gc – globulin): multiple tasks. J Steroid Biochem Mol Biol 1995: 53: 579582.
  • 46
    Bikle D D, Halloran B P, Gee E, Ryzen E, Haddad J G. Free 25-hydroxyvitamin D levels are normal in subjects with liver diseases and reduced total 25-hydroxyvitamin D levels. J Clin Invest 1986: 78: 748752.
  • 47
    Mendel C M. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev 1989: 10: 232274.
  • 48
    Rowling M J, Kemmis C M, Taffany D A et al. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr 2006: 136: 27542759.
  • 49
    Nykjaer A, Dragun D, Walther D et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999: 96: 507515.
  • 50
    Lehmann B, Sauter W, Knuschke P, Dreßler S, Meurer M. Demonstration of UVB-induced synthesis of 1α,25-dihydroxyvitamin D3 (calcitriol) in human skin by microdialysis. Arch Dermatol Res 2003: 295: 2428.
  • 51
    Bär M, Domaschke D, Meye A, Lehmann B, Meurer M. Wavelength-dependent induction of CYP24A1-mRNA after UVB-triggered calcitriol synthesis in cultured human keratinocytes. J Invest Dermatol 2007: 127: 206213.
  • 52
    Masuda S, Kamao M, Schroeder N J et al. Characterization of 3-epi-1α,25-dihydroxyvitamin D3 involved in 1α,25-dihydroxyvitamin D3 metabolic pathway in cultured cell lines. Biol Pharm Bull 2000: 23: 133139.
  • 53
    Nemanic M K, Bikle D, Elias P M. Hormonal regulation of vitamin D3 production in human foreskin keratinocytes. Calcif Tissue Int 1983: 35 (Suppl): 700.
  • 54
    Schuster I, Herzig G, Vorisek G. Steroidal hormones as modulators of vitamin D metabolism in human keratinocytes. In: NormanA W, BouillonR, ThomassetM, eds. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications. Proceedings of the Ninth Workshop on Vitamin D, Orlando, FL (USA), May 28–June 2, 1994. New York: Walter de Gruyter, 1994: 184185.
  • 55
    Vantieghem K, De Haes P, Bouillon R, Segaert S. Dermal fibroblasts pretreated with a sterol delta7-reductase inhibitor produce 25-hydroxyvitamin D3 upon UVB irradiation. J Photochem Photobiol 2006: 85: 7278.
  • 56
    Binkley N, Novotny R, Krueger D et al. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab 2007: 92: 21302135.
  • 57
    Jacob A I, Sallman A, Santiz Z, Hollis B W. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 1984: 114: 13131319.
  • 58
    Rogers S, Marks J, Shuster S, Hillyard C J. Effect of PUVA on serum 25-OH vitamin D in psoriatics. Br Med J 1979: 2: 833834.
  • 59
    Shuster S, Chadwick L, Moss C, Marks J. Serum 25-OH vitamin D after photochemotherapy. Br J Dermatol 1981: 105: 421423.
  • 60
    Norman T C, Norman A W. Considerations of chemical mechanisms for the nonphotochemical production of vitamin D3 in biological systems. Bioorg Med Chem Lett 1993: 9: 17851788.
  • 61
    Reichrath J, Classen U G, Meineke V et al. Immunoreactivity of six monoclonal antibodies directed against 1,25-dihydroxyvitamin-D3 receptors in human skin. Histochem J 2000: 32: 625629.
  • 62
    Carlberg C. RXR-independent action of the receptors for thyroid hormone, retinoid acid and vitamin D on inverted palindromes. Biochem Biophys Res Commun 1993: 195: 13451353.
  • 63
    Forman B M, Casanova J, Raaka B M, Ghysdael J, Samuels H H. Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers. Mol Endocrinol 1992: 6: 429442.
  • 64
    Kliewer S A, Umesono K, Mangelsdorf D J, Evans R M. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992: 355: 446449.
  • 65
    Schräder M, Müller K M, Nayeri S, Kahlen J P, Carlberg C. Vitamin D3-thyroid hormone receptor heterodimer polarity directs ligand sensitivity of transactivation. Nature 1994: 370: 382386.
  • 66
    Takeshita A, Ozawa Y, Chin W W. Nuclear receptor coactivators facilitate vitamin D receptor homodimer action on direct repeat hormone response elements. Endocrinology 2000: 141: 12811284.
  • 67
    Olson D P, Koenig R J. 5’-Flanking sequences in thyroid hormone response element half-sites determine the requirement of retinoid X receptor for receptor-mediated gene expression. J Biol Chem 1997: 272: 99079914.
  • 68
    Thompson P D, Hsieh J C, Whitfield G K et al. Vitamin D receptor displays DNA binding and transactivation as a heterodimer with the retinoid X receptor, but not with the thyroid hormone receptor. J Cell Biochem 1999: 750: 462480.
  • 69
    Carlberg C, Saurat J H. Vitamin D-retinoid association: molecular basis and clinical applications. J Investig Dermatol Symp Proc 1996: 1: 8286.
  • 70
    Ellison T I, Eckert R L, MacDonald P N. Evidence for 1,25-dihydroxyvitamin D3-independent transactivation by the vitamin D receptor. J Biol Chem 2007: 282: 1095310962.
  • 71
    Hawker N P, Pennypacker S D, Chang S M, Bikle D D. Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3. J Invest Dermatol 2007: 127: 874880.
  • 72
    Shah S, Islam M N, Dakshanamurthy S et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 2006: 21: 799809 [Erratum in: Mol Cell 2006: 22: 148].
  • 73
    Courtois S J, Segaert S, Degreef H, Bouillon R, Garmyn M. Ultraviolet B suppresses vitamin D receptor gene expression in keratinocytes. Biochem Biophys Res Commun 1998: 246: 6469.
  • 74
    Wang Z, Boudjelal M, Kang S, Voorhees J J, Fisher G J. Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment. Nat Med 1999: 5: 1822 [Erratum in: Nat Med 1999: 5: 849].
  • 75
    Ellison T I, Smith M K, Gilliam A C, Macdonald P N. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigeneis. J Invest Dermatol 2008: 128: 25082517.
  • 76
    Segaert S, Bouillon R. Epidermal keratinocytes as source and target cells for vitamin D. In: NormanA W, BouillonR, ThomassetM, eds. Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects. Proceedings of the Eleventh Workshop on Vitamin D, Nashville, TN, USA, May 27–June 1, 2000. Printing and Reprographics Riverside: University of California 2000: 583590.
  • 77
    Lu J, Goldstein K M, Chen P, Huang S, Gelbert L M, Nagpal S. Transcriptional profiling of keratinocytes reveals a vitamin D-regulated epidermal differentiation network. J Invest Dermatol 2005: 124: 778785.
  • 78
    Akutsu N, Lin R, Bastien Y et al. Regulation of gene expression by 1α,25-dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol Endocrinol 2001: 15: 11271139.
  • 79
    Segaert S, Garmyn M, Degreef H, Bouillon R. Retinoic acid modulates the anti-proliferative effect of 1,25-dihydroxyvitamin D3 in cultured human epidermal keratinocytes. J Invest Dermatol 1997: 109: 4654.
  • 80
    Matsumoto K, Hashimoto K, Nishida Y, Hashiro M, Yoshikawa K. Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun 1990: 166: 916923.
  • 81
    Sebag M, Gulliver W, Kremer R. Effect of 1,25 dihydroxyvitamin D3 and calcium on growth and differentiation and on c-fos and p53 gene expression in normal human keratinocytes. J Invest Dermatol 1994: 103: 323329.
  • 82
    Kim H J, Abdelkader N, Katz M, McLane J A. 1,25-Dihydroxy-vitamin-D3 enhances antiproliferative effect and transcription of TGF-beta1 on human keratinocytes in culture. J Cell Physiol 1992: 151: 579587.
  • 83
    Haugen J D, Pittelkow M R, Zinsmeister A R, Kumar R. 1α,25-Dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increasing transforming growth factor β2 release. Biochem Biophys Res Commun 1996: 229: 618623.
  • 84
    Lin R, Wang T T, Miller W H, White J H. Inhibition of F-box protein p45SKP2 expression and stabilization of cyclin-dependent kinase inhibitor p27KIP1 in vitamin D analogue-treated cancer cells. Endocrinology 2003: 144: 749753.
  • 85
    Kremer R, Karaplis A C, Henderson J et al. Regulation of parathyroid hormone-like peptide in cultured normal human keratinocytes. Effect of growth factors and 1,25 dihydroxyvitamin D3 on gene expression and secretion. J Clin Invest 1991: 87: 884893.
  • 86
    Garach-Jehoshua O, Ravid A, Liberman U A, Koren R. 1,25-Dihydroxyvitamin D3 increases the growth-promoting activity of autocrine epidermal growth factor receptor ligands in keratinocytes. Endocrinology 1999: 140: 713721.
  • 87
    Wang T T, Tavera-Mendoza L E, Laperriere D et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005: 19: 26852695.
  • 88
    Xie S P, Pirianov G, Colston K W. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer 1999: 35: 17171723.
  • 89
    Peng L, Malloy P J, Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004: 18: 11091119.
  • 90
    Hughes S V, Robinson E, Bland R, Lewis H M, Stewart P M, Hewison M. 1,25-dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes. Endocrinology 1997: 138: 37113718.
  • 91
    Kobayashi T, Pittelkow M R, Warner G M, Squillace K A, Kumar R. Regulation of a novel immediate early response gene, IEX-1, in keratinocytes by 1α,25-dihydroxyvitamin D3. Biochem Biophys Res Commun 1998: 251: 868873.
  • 92
    Im H J, Craig T A, Pittelkow M R, Kumar R. Characterization of a novel hexameric repeat DNA sequence in the promoter of the immediate early gene, IEX-1, that mediates 1α,25-dihydroxyvitamin D3-associated IEX-1 gene repression. Oncogene 2002: 21: 37063714.
  • 93
    Kumar R, Pittelkow M R, Salisbury J L et al. A novel vitamin D-regulated immediate-early gene, IEX-1, alters cellular growth and apoptosis. Recent Results Cancer Res 2003: 164: 123134.
  • 94
    Lehen’kyi V, Beck B, Polakowska R et al. TRPV6 is a Ca2+ entry channel essential for Ca2+-induced differentiation of human keratinocytes. J Biol Chem 2007: 282: 2258222582.
  • 95
    Koli K, Keski-Oja J. Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes. J Invest Dermatol 1993: 101: 706712.
  • 96
    Xie Z, Bikle D D. Cloning of the human phospholipase C-gamma1 promoter and identification of a DR6-type vitamin D-responsive element. J Biol Chem 1997: 272: 65736577.
  • 97
    Xie Z, Bikle D D. Phospholipase C-γ1 is required for calcium-induced keratinocyte differentiation. J Biol Chem 1999: 274: 2042120424.
  • 98
    Bikle D D. Vitamin D and skin cancer. J Nutr 2004: 12 (Suppl): 3472S3478S.
  • 99
    Dai X, Sayama K, Shirakata Y et al. PPARgamma is an important transcription factor in 1alpha,25-dihydroxyvitamin D3-induced involucrin expression. J Dermatol Sci 2008: 50: 5360.
  • 100
    Lippens S, Kockx M, Denecker G et al. Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures. Am J Pathol 2004: 165: 833841.
  • 101
    Geilen C C, Bektas M, Wieder T, Kodelja V, Goerdt S, Orfanos C E. 1alpha,25-Dihydroxyvitamin D3 induces sphingomyelin hydrolysis in HaCaT cells via tumor necrosis factor alpha. J Biol Chem 1997: 272: 89979001.
  • 102
    Carlberg C, Polly P. Gene regulation by vitamin D3. Crit Rev Eukaryot Gene Expr 1998: 8: 1942.
  • 103
    Zhang J Z, Maruyama K, Ono I, Iwatsuki K, Kaneko F. Regulatory effects of 1,25-dihydroxyvitamin D3 and a novel vitamin D3 analogue MC903 on secretion of interleukin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1). J Dermatol Sci 1994: 7: 2431.
  • 104
    Fukuoka M, Ogino Y, Sato H et al. RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol). Br J Dermatol 1998: 138: 6370.
  • 105
    Michel G, Gailis A, Jarzebska-Deussen B, Müschen A, Mirmohammadsadegh A, Ruzicka T. 1,25-(OH)2-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 1997: 46: 3234.
  • 106
    Zhang J Z, Maruyama K, Ono I, Kaneko F. Production and secretion of platelet-derived growth factor AB by cultured human keratinocytes: regulatory effects of phorbol 12-myristate 13-acetate, etretinate,1,25-dihydroxyvitamin D3, and several cytokines. J Dermatol 1995: 22: 305309.
  • 107
    Carlberg C. Molecular mechanisms of action of vitamin D. In: KnutKragballe, ed. Vitamin D in Dermatology. New York: Marcel Dekker Basel, 2000: 126.
  • 108
    Wang T T, Nestel F P, Bourdeau V et al. Cutting edge: 1, 25-Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004: 173: 29092912.
  • 109
    Gombard H F, Borregaard N, Koeffler H P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005: 19: 10671077.
  • 110
    Gniadecki R. Stimulation versus inhibition of keratinocyte growth by 1,25-Dihydroxyvitamin D3: dependence on cell culture conditions. J Invest Dermatol 1996: 106: 510516.
  • 111
    Bikle D D. Vitamin D regulated keratinocyte differentiation. J Cell Biochem 2004: 92: 436444.
  • 112
    Oda Y, Ishikawa M H, Hawker N P, Yun Q C, Bikle D D. Differential role of two VDR coactivators, DRIP205 and SRC-3, in keratinocyte proliferation and differentiation. J Steroid Biochem Mol Biol 2007: 103: 776780.
  • 113
    Segaert S, Garmyn M, Degreef H, Bouillon R. Suppression of vitamin D receptor and induction of retinoid X receptor α expression during squamous differentiation of cultured keratinocytes. J Invest Dermatol 2000: 114: 494501.
  • 114
    Ohta S, Nitta N, Takahashi M et al. Pluronic F127: Application in arterial embolization. J Vasc Interv Radiol 2006: 17: 533539.
  • 115
    Cohen L B, Salzberg B M, Davila H V, Ross W N. Changes in axon fluorescence during activity: molecular probes of membrane potential. J Membr Biol 1974: 19: 136.
  • 116
    Chen T C, Persons K S, Lu Z L, Mathieu S, Holick M F. An evaluation of the biologic activity and vitamin D receptor binding affinity of the photoisomers of vitamin D3 and previtamin D3. J Nutr Biochem 2000: 11: 267272.
  • 117
    Popadic S, Ramic Z, Medenica L et al. Antiproliferative effect of vitamin A and D analogues on adult human keratinocytes in vitro. Skin Pharmacol Physiol 2008: 21: 227234.
  • 118
    Ray S, Ray R, Holick M F. Psoriatic keratinocytes metabolize 3H-1α,25-dihydroxyvitamin D3 at a rate faster than the normal keratinocytes. In: NormanA W, BouillonR, ThomassetM, eds. Vitamin D Apluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications. Proceedings of the Ninth Workshop on Vitamin D, Orlando, FL, USA, May 28–June 2, 1994. Berlin/New York: Walter de Gruyter, 1994: 598599.
  • 119
    Manggau M, Kim D S, Ruwisch L et al. 1α,25-Dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol 2001: 117: 12411249.
  • 120
    Sato T, Imai N, Akimoto N, Sakiguchi T, Kitamura K, Ito A. Epidermal growth factor and 1α,25-dihydroxyvitamin D3 suppress lipogenesis in hamster sebaceous gland cells in vitro. J Invest Dermatol 2001: 117: 965970.
  • 121
    Lee D Y, Yamasaki K, Rudsil J et al. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. J Invest Dermatol 2008: [Epub ahead of print].
  • 122
    Weber G, Heilborn J D, Chamorro-Jimenez C L, Hammarsjö A, Törmä H, Ståhle M. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol 2005: 124: 10801082.
  • 123
    Reichrath J, Schuler C H, Seifert M, Zouboulis C H, Tillgen W. The vitamin D endocrine sytem of human sebocytes. Exp Dermatol 2006: 15: 643.
  • 124
    Zouboulis C C, Seltmann H, Neitzel H, Orfanos C E. Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol 1999: 113: 10111020.
  • 125
    Skorija K, Cox M, Sisk J M et al. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol Endocrinol 2005: 19: 855862.
  • 126
    Bikle D D, Chang S, Crumrine D et al. 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J Invest Dermatol 2004: 122: 984992.
  • 127
    Demay M B. Mechanism of vitamin D receptor action. Ann NY Acad Sci 2006: 1068: 204213.
  • 128
    Xie Z, Chang S, Oda Y, Bikle D D. Hairless suppresses vitamin D receptor transactivation in human keratinocytes. Endocrinology 2006: 147: 314323.
  • 129
    Bikle D D, Elalieh H, Chang S, Xie Z, Sundberg J P. Development and progression of alopecia in the vitamin D receptor null mouse. J Cell Physiol 2006: 207: 340353.
  • 130
    Li M, Indra A K, Warot X et al. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature 2000: 407: 633636.
  • 131
    Li M, Chiba H, Warot X et al. RXR-alpha ablation in skin keratinocytes results in alopecia and epidermal alterations. Development 2001: 128: 675688.
  • 132
    Jimenez J J, Yunis A A. Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3. Cancer Res 1992: 52: 51235125.
  • 133
    Paus R, Schilli M B, Handjiski B, Menrad A, Henz B M, Plonka P. Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res 1996: 56: 44384443.
  • 134
    Hidalgo M, Rinaldi D, Medina G, Griffin T, Turner J, Von Hoff D D. A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anticancer Drugs 1999: 10: 393395.
  • 135
    Sigmundsdottir H, Pan J, Debes G F et al. DCs metabolize sunlight-induced vitamin D3 to “program” T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007: 8: 285293.
  • 136
    Gorman S, Kuritzky L A, Judge M A et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+ CD25+ cells in the draining lymph nodes. J Immunol 2007: 179: 62736283.
  • 137
    Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulators T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 2003: 88: 227233.
  • 138
    Griffin M, Kumar R. Effects of 1α,25-Dihydroxyvitamin D3 and its analogs on dendritic cell function. J Cell Biochem 2003: 88: 323326.
  • 139
    Heine G, Anton K, Henz B M, Worm M. 1alpha,25-dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. Eur J Immunol 2002: 32: 33953404.
  • 140
    Katayama I, Minatohara K, Yokozeki H, Nishioka K. Topical vitamin D3 downregulates IgE-mediated murine biphasic cutaneous reactions. Int Arch Allergy Immunol 1996: 111: 7176.
  • 141
    Li M, Hener P, Zhang Z, Kato S, Metzger D, Chambon P. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 2006: 103: 1173611741.
  • 142
    Soumelis V, Reche P A, Kanzler H et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002: 3: 673680.
  • 143
    Gottlieb A B. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol 2005: 53: S3S16.
  • 144
    Lack G. Epidemiologic risks for food allergy. J Allergy Clin Immunol 2008: 121: 13311336.
  • 145
    Zasloff M. Fighting infections with vitamin D. Nat Med 2006: 12: 388390.
  • 146
    Zasloff M. Sunlight, vitamin D, and the innate immune defenses of the human skin. J Invest Dermatol 2005: 125: xvixvii.
  • 147
    Mallbris L, Edström D W, Sundblad L, Granath F, Stahle M. UVB upregulates the antimicrobial protein hCAP18 mRNA in human skin. J Invest Dermatol 2005: 125: 10721074.
  • 148
    Schauber J, Dorschner R A, Coda A B et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007: 117: 803811.
  • 149
    Liu P T, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006: 311: 17701773.
  • 150
    Klein G L, Chen T C, Holick M F et al. Synthesis of vitamin D in skin after burns. Lancet 2004: 363: 291292.
  • 151
    Wolpowitz D, Gilchrest B A. The vitamin D questions: how much do you need and how should you get it? J Am Acad Dermatol 2006: 54: 301317.
  • 152
    Sebag M, Henderson J, Rhim J, Kremer R. Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression. J Biol Chem 1992: 267: 12162121167.
  • 153
    Ratnam A V, Bikle D D, Su M J, Pillai S. Squamous carcinoma cell lines fail to respond to 1,25-Dihydroxyvitamin D despite normal levels of the vitamin D receptor. J Invest Dermatol 1996: 106: 522525.
  • 154
    Bikle D D, Pillai S, Gee E. Squamous carcinoma cell lines produce 1,25 dihydroxyvitamin D, but fail to respond to its prodifferentiating effect. J Invest Dermatol 1991: 97: 435441.
  • 155
    Bikle D D, Xie Z, Ng D, Tu C L, Oda Y. Squamous cell carcinomas fail to respond to the prodifferentiating actions of 1,25(OH)2D: why? Recent Results Cancer Res 2003: 164: 111122.
  • 156
    De Haes P, Garmyn M, Verstuyf A et al. Two 14-epi analogues of 1,25-dihydroxyvitamin D3 protect human keratinocytes against the effects of UVB. Arch Dermatol Res 2004: 12: 527534.
  • 157
    De Haes P, Garmyn M, Carmeliet G et al. Molecular pathways involved in the anti-apoptotic effect of 1,25-dihydroxyvitamin D3 in primary human keratinocytes. J Cell Biochem 2004: 93: 951967.
  • 158
    De Haes P, Garmyn M, Verstuyf A et al. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J Photochem Photobiol B 2005: 78: 141148.
  • 159
    Dixon K M, Deo S S, Wong G et al. Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol 2005: 97: 137143.
  • 160
    Dixon K M, Deo S S, Norman A W et al. In vivo relevance for photoprotection by the vitamin D rapid response pathway. J Steroid Biochem Mol Biol 2007: 103: 451456.
  • 161
    Gupta R, Dixon K M, Deo S S et al. Photoprotection by 1,25-dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. J Invest Dermatol 2007: 127: 707715.
  • 162
    Hollander M C, Sheikh M S, Bulavin D V et al. Genomic instability in Gadd45α-deficient mice. Nat Genet 1999: 23: 176184.
  • 163
    Lin R, White J H. The pleiotropic actions of vitamin D. Bio Essays 2003: 26: 2128.
  • 164
    Reichrath J. Vitamin D and the skin: an ancient friend revisited. Exp Dermatol 2007: 16: 618625.
  • 165
    Holm E A, Jemec G B. The therapeutic potential of calcipotriol in diseases other than psoriasis. Int J Dermatol 2002: 41: 3843.
  • 166
    Gupta A K, Browne M, Bluhm R. Nonpsoriatic uses of calcipotriol. J Cutan Med Surg. 2002: 6: 442448.
  • 167
    Reichrath J. Will analogs of 1,25-dihydroxyvitamin D3 (calcitriol) open a new era in cancer therapy? Onkologie 2001: 24: 128133.
  • 168
    Reichrath J, Lehmann B, Carlberg C, Varani J, Zouboulis C C. Vitamins as hormones. Horm Metab Res 2007: 39: 7184.
  • 169
    Huang D C, Papavasiliou V, Rhim J S, Horst R L, Kremer R. Targeted disruption of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in ras-transformed keratinocytes demonstrates that locally produced 1alpha,25-dihydroxyvitamin D3 suppresses growth and induces differentiation in an autocrine fashion. Mol Cancer Res 2002: 1: 5667.
  • 170
    Schuster I, Bernhardt R. Inhibition of cytochromes p450: existing and new promising therapeutic targets. Drug Metab Rev 2007: 39: 481499.